Galapagos NV (Galapagos) is a publicly held research focused biopharmaceutical company. It is engaged in discovery and development of disease modifying drugs. The company develops GLPG0259 that targets protein kinase MAPKAPK5, as its leading drug candidate for the under initial stages of clinical trials. Its products include metastasis, cachexia, metabolic, Alzheimer's, bone: mAbs, ra/ms flares, osteoporosis, infections and copd in various stages of development. The company operates through two divisions namely; drug discovery and BioFocus DPI. Under its drug discovery division, the company develops small molecule programs in the fields of bone metastasis, bone and joint diseases, anti-infectives, cachexia and metabolic diseases. The company is also into developing new antibody therapies for bone and joint diseases through an alliance with MorphoSys. The company offers target-to-drug discovery products and services to pharmaceutical and biotech companies through its BioFocus DPI division. In October 2009, Galapagos expanded its global strategic alliance with an affiliate of Merck & Co. Inc. for the development of new therapies for atherosclerosis in the fields of metabolic diseases. Recently, the company entered into a global multi-year strategic alliance with Roche Holding Ltd, to develop potential novel treatments for COPD (chronic obstructive pulmonary disease). This collaboration will enable both the partners to discover new potential drugs for COPD and will bring new mode of action drugs for COPD into the clinic for Roche. Galapagos is headquartered in Mechelen, Belgium.